Vaccibody AS, of Oslo, Norway, said it filed a clinical trial application for its cancer neoantigen vaccine, VB10.NEO, with German regulatory authority Paul Ehrlich Institute to run a phase I/IIa trial evaluating the safety, feasibility and efficacy of VB10.NEO in combination with standard-of-care checkpoint inhibitor therapy in patients with locally advanced or metastatic non-small-cell lung cancer, melanoma, renal cancer, bladder and head and neck cancer.